A big leg up for brachyury drug discovery
Dr. David Drewry. Photo by Jeyhoun Allebaugh/UNC-Chapel Hill Discovering drugs that strike at brachyury, the Achilles’ heel of chordoma, likely … Continue reading
Dr. David Drewry. Photo by Jeyhoun Allebaugh/UNC-Chapel Hill Discovering drugs that strike at brachyury, the Achilles’ heel of chordoma, likely … Continue reading
In 2017 we launched our ALL IN campaign: an ambitious $16M initiative aiming to seize extraordinary opportunities in chordoma research … Continue reading
In recent years, researchers have identified chordoma’s Achilles’ heel: a protein called brachyury, which drives and sustains the cancer. To date, attacking brachyury has been an uphill battle. But new research has helped illuminate the path forward: with support from the Chordoma Foundation, scientists demonstrated that brachyury could be directly degraded and that doing so caused chordoma cells to stop growing. Continue reading
The Chordoma Foundation (CF) and The Mark Foundation for Cancer Research (MFCR) announced today a two-year, $1.4M partnership with a team of researchers at three institutions to develop new treatments for chordoma, a rare and difficult-to-treat bone cancer. The researchers will focus on creating the first drugs to inhibit a protein known as brachyury. Continue reading
I’m excited to share the findings of a new paper published earlier this week in the journal Nature Medicine that … Continue reading
We are pleased to announce that the Chordoma Foundation and The Mark Foundation for Cancer Research (MFCR) have together awarded … Continue reading